Effects of Insulin-Like Growth Factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages 4361-4366

  Rao, Madhu N ^a,c   Mulligan, Kathleen ^a,c   Tai, Viva ^c   Wen, Michael J ^a,c   Dyachenko, Artem ^d   Weinberg, Melissa ^a   Li, Xiaojuan ^b   Lang, Thomas ^b   Grunfeld, Carl ^a,e   Schwarz, Jean Marc ^a,c,d   Schambelan, Morris ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d TOURO UNIVERSITY CALIFORNIA   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; ISOTOPE; MECASERMIN RINFABATE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TESTOSTERONE; TRIACYLGLYCEROL; DRUG COMBINATION; GLUCOSE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ABDOMINAL OBESITY; ADULT; ARTHRALGIA; ARTICLE; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LEG EDEMA; LIPOGENESIS; LIPOLYSIS; MALE; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PILOT STUDY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID METABOLISM; METABOLISM; MIDDLE AGED; OBESITY, ABDOMINAL; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

ADIPOSE TISSUE; BODY COMPOSITION; BODY FAT DISTRIBUTION; DRUG COMBINATIONS; GLUCOSE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PILOT PROJECTS;

EID: 77956562598     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2502     Document Type: Article

References (21)

1. Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS 2002 Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 31:257-275
2. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD 2003 Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993-2003
3. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, Schambelan M 2001 The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86:3480-3487
4. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, Bock D, Simons G, Gertner JM 2004 Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 35:239-252
5. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S 2007 Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357:2359-2370
6. Clemmons DR, Underwood LE 1992 Role of insulin-like growth factors and growth hormone in reversing catabolic states. Horm Res 38(Suppl 2):37-40
7. Kim RJ, Grimberg A 2007 Potential non-growth uses of rhIGF-1. Growth Genet Horm 23:1-7
8. Mauras N, Martinez V, Rini A, Guevara-Aguirre J 2000 Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 85:3036-3042
9. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J 2000 The combination of insulin-like growth factor 1 and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85:1518-1524
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
11. Schwarz JM, Mulligan K, Lee J, Lo JC, Wen M, Noor MA, Grunfeld C, Schambelan M 2002 Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 87:942-945 (Pubitemid 34158275)
12. Snijder MB, Visser M, Dekker JM, Seidell JC, Fuerst T, Tylavsky F, Cauley J, Lang T, Nevitt M, Harris TB 2002 The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. Int J Obes Relat Metab Disord 26:984-993
13. Li X, Youngren JF, Hyun B, Sakkas GK, Mulligan K, Majumdar S, Masharani UB, Schambelan M, Goldfine ID 2008 Technical evaluation of in vivo abdominal fat and IMCL quantification using MRI and MRSI at 3 T. Magn Reson Imaging 26:188-197
14. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-502
15. Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB 2006 Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 55:2365-2370
16. Cusi K, DeFronzo R 2000 Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 85:3077-3084
17. Tayek JA and Katz J 1997 Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: relationship to serum cortisol. Am J Physiol Endo Metab 272(35):E476-E484
18. Yki-Järvinen H, Mäkimattila S, Utriainen T, Rutanen EM 1995 Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 80:3227-3232
19. Grunfeld C, Rimland D, Gibert CL, Powderly WG, Sidney S, Shlipak MG, Bacchetti P, Scherzer R, Haffner SM, Heymsfield SB 2007 Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immun Defic Syndr 46:283-290
20. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL 2000 Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6:77-86
21. Schwarz JM, Linfoot P, Dare D, Aghajanian K 2003 Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77:43-50